SCHEMBL5135636

SCHEMBL5135636

O=C1NC(=O)[C@@]2(C(=O)Nc3ccc(F)cc32)N1Cc1ccc(C(F)(F)F)cc1F

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.37
CYP1A2 P05177 1/20 0.36
MAPT P10636 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
IDO1 P14902 1/20 0.35
RIPK3 Q9Y572 3/20 0.35
AKR1B1 P15121 6/20 0.34
NTRK1 P04629 2/20 0.34
AKR1B10 O60218 1/20 0.34
AKR1A1 P14550 1/20 0.34
MOGAT2 Q3SYC2 1/20 0.34
NTRK3 Q16288 1/20 0.34
NTRK2 Q16620 1/20 0.34
HDAC1 Q13547 1/20 0.33
HDAC8 Q9BY41 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
PKM P14618 1/20 0.32
PKLR P30613 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4976851 0.87 TRAP1 (0.39) CYP1A2MAPTCYP2C19KMT2AAKR1B1
SCHEMBL5135639 0.78 AKR1B1 (0.38) DAOCYP1A2MAPTCYP2C19KMT2A
SCHEMBL3957233 0.71 CYP1A2 (0.39) CYP1A2MAPTCYP2C19KMT2AAKR1B1
SCHEMBL3950564 0.71 CYP1A2 (0.43) CYP1A2MAPTCYP2C19KMT2AAKR1B1
SCHEMBL4979292 0.71 CYP1A2 (0.43) CYP1A2MAPTCYP2C19KMT2AAKR1B1
SCHEMBL4977915 0.69 KDM4E (0.42) CYP1A2MAPTCYP2C19KMT2A
SCHEMBL4263802 0.68 AKR1B1 (0.43) AKR1B1AKR1B10AKR1A1
SCHEMBL3952569 0.68 OPRM1 (0.44) CYP1A2MAPTCYP2C19KMT2AAKR1B1
SCHEMBL4976847 0.65 TRAP1 (0.39) CYP1A2MAPTCYP2C19KMT2AAKR1B1
SCHEMBL27634838 0.64 IDO1 (0.58) DAOIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1984374-A1 USE OF SPIRO Ý IMIDAZOLIDINE-4, 3'-INDOLE¨2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 AstraZeneca AB (SE) 2008-10-29 EP claimed
WO-2007091946-A1 USE OF SPIRO [ IMIDAZOLIDINE-4, 3'-INDOLE] 2, 2', 5' (1H) TRIONES FOR TREATMENT OF CONDITIONS ASSOCIATED WITH VANILLOID RECEPTOR 1 ASTRAZENECA AB (SE) 2007-08-16 WO claimed